Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine

Background: OnabotulinumtoxinA and calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) target different migraine pathways, therefore, combination treatment may provide additional effectiveness for the preventive treatment of chronic migraine (CM) than either treatment alone. The obje...

Descripción completa

Detalles Bibliográficos
Autores principales: Mechtler, Laszlo, Saikali, Nicolas, McVige, Jennifer, Hughes, Olivia, Traut, Alexandra, Adams, Aubrey Manack
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770868/
https://www.ncbi.nlm.nih.gov/pubmed/35069416
http://dx.doi.org/10.3389/fneur.2021.788159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770868/
https://www.ncbi.nlm.nih.gov/pubmed/35069416
http://dx.doi.org/10.3389/fneur.2021.788159

Ejemplares similares